Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3Lung Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Laryngeal Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2COVID-19 2Xerostomia Due to Radiotherapy (Disorder) 1Stroke 1Sleep Initiation and Maintenance Disorders 1Signs and Symptoms 1Pulmonary Disease, Chronic Obstructive 1Patient Acceptance of Health Care 1Pain, Intractable 1Pain 1Oropharyngeal Neoplasms 1Organoids 1Obesity, Abdominal 1Mouth Neoplasms 1Lymphoma, Follicular 1Kidney Failure, Chronic 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Head and Neck Carcinoma 1Glioma 1Diabetes Mellitus 1Delirium 1Death 1Coronary Artery Disease 1

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Stroke × Standard of Care × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡